search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Michael A Augello ,
Deli Liu ,
Lesa D Deonarine ,
Brian D Robinson ,
Dennis Huang ,
Suzan Stelloo ,
Mirjam Blattner ,
Ashley S Doane ,
Elissa W P Wong ,
Yu Chen ,
Mark A Rubin ,
Himisha Beltran ,
Olivier Elemento ,
Andries M Bergman ,
Wilbert Zwart ,
Andrea Sboner ,
Noah Dephoure ,
Christopher E Barbieri

Abstract

Deletion of the gene encoding the chromatin remodeler CHD1 is among the most common alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and reasons for its tissue-specific loss remain undefined. We demonstrated that CHD1 occupied prostate-specific enhancers enriched for the androgen receptor (AR) and lineage-specific cofactors. Upon CHD1 loss, the AR cistrome was redistributed in patterns consistent with the oncogenic AR cistrome in PCa samples and drove tumor formation in the murine prostate. Notably, this cistrome shift was associated with a unique AR transcriptional signature enriched for pro-oncogenic pathways unique to this tumor subclass. Collectively, these data credential CHD1 as a tumor suppressor in the prostate that constrains AR binding/function to limit tumor progression.

More about this publication

Cancer cell

Volume 35
Issue nr. 4
Pages 603-617.e8
Publication date 15-04-2019

Full text links

Publisher website (DOI) 10.1016/j.ccell.2019.03.001
Europe PubMed Central 30930119
Pubmed 30930119

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.